Japanese study of Linagliptin for type 2 diabetes patients with NAFLD in Kagoshima - J-LINK study

Japan society of Patient Reported Outcome0 个研究点目标入组 48 人开始时间: 2014年8月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Person who correspond to any of following will be excluded; Exclusion Criteria; 1.Type1 diabetes or secondary diabetes 2.Current use of warfarin potassium 3.Hepatitis B surface antigen positive or HCV antibody positive 4.Has severe injury, severe infection or an operation scheduled within one year 5.MI, AP, or CI in 12 weeks before obtaining informed consent 6.Atrial fibrillation or frequent ventricular ectopy 7.Moderate or greater cardiac insufficiency ,stage 3 or higher of New York Heart Association classification. 8.AST or ALT is 5 times higher or greater than normal values ,values differ among the hospitals 9.Alpha1 antitrypsin deficiency,Wilson's disease,primary biliary cirrhosis(PBC),or serum creatinine is twice higher than normal values 10.Ascites, encephalopathia 11.Possible labile hypertension or instability lipid abnormality found twelve weeks before obtaining informed consent 12.Alcohol or drug addiction 13.Pregnant, breast feeding, or possible pregnancy 14.Anyone who falls into contraindicated conditions 15.Any condition that may raise doctor concern

发起方

Japan society of Patient Reported Outcome